Topics

Companies Related to "Sarepta Therapeutics playing nice with over rejection Duchenne" [Most Relevant Company Matches] RSS

14:12 EST 5th December 2019 | BioPortfolio

Here are the most relevant search results for "Sarepta Therapeutics playing nice with over rejection Duchenne" found in our extensive corporate database of over 50,000 company records.

Showing "Sarepta Therapeutics playing nice with over rejection Duchenne" Companies 1–25 of 1,900+

Extremely Relevant

Sarepta Therapeutics, Inc.

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most ...


Sarepta Therapeutics

Innovative RNA-Based Technology; First-in-Class Therapeutics Sarepta Therapeutics – formerly AVI BioPharma – remains focused on developing first-in-class, RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. Sarepta’s unique technology has yielded a diverse pipeline of RNA-based therapeutics that...

CureDuchenne Ventures LLC

CureDuchenne Ventures LLC collaborates with pharmaceutical and biotechnology companies to facilitate the development of drugs to treat Duchenne muscular dystrophy. CureDuchenne Ventures LLC was formed by CureDuchenne, a national nonprofit that has funded seven research projects that have advanced to human clinical trials. CureDuchenne has leveraged $100 mi...


Relevant

Akashi Therapeutics

Akashi Therapeutics is a clinical stage biopharmaceutical company whose mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts to impact a central problem in rare ...

Akashi Therapeutics, Inc.

Akashi Therapeutics is a clinical stage biopharmaceutical company whose mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts to impact a central problem i...

Akashi Therapeutics Inc.

Akashi Therapeutics is a clinical stage biopharmaceutical company whose mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts to impact a central problem in rare ...

That's Nice LLC

That's Nice is a full-service agency providing brand and marketing management with value-added business support. Its brand represents years of knowledge in client markets, a passion for strategic thinking and comprehensive services that meet the needs of global companies.

National Institute for Health and Clinical Excellence

The National Institute for Health and Clinical Excellence (NICE) is the independent organisation responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health.NICE has a number of staff based at our London and Manchester offices who deliver the Institute’s work.NICE guidance is developed by a number of independent advisory groups made ...

JAR of Hope

JAR of Hope was founded in 2013 by James Raffone, after his young son, Jamesy, was diagnosed with Duchenne muscular dystrophy. Duchenne is a form of muscular dystrophy that is caused by a mutation in the dystrophin gene. The absence of dystrophin results in muscle deterioration—leading to paralysis, decreased cardiac function, and eventual death. Duch...

Cure Duchenne

Cure Duchenne, a national nonprofit organization located in Newport Beach, Calif., is gaining international attention for its efforts to raise funds and awareness for Duchenne – a devastating and lethal muscle disease in children. One in every 3,500 male births results in a child being afflicted with the disease. Nearly 20,000 boys are living with the ...

Trillium Therapeutics Inc

Trillium Therapeutics Inc. (TTI), a research-driven biopharmaceutical company with a strong immunology focus, specializes in the discovery and development of innovative therapies for the treatment of immune-mediated disorders. The company’s therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant and harmful immune responses, such as autoi...

CHU de Nice

Nil

Nice Systems Ltd.

Nice Ride Minnesota

Argos Therapeutics

Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www.a...

Jett Foundation

Based in Kingston, MA the Jett Foundation is a non-profit organization dedicated to increasing worldwide awareness of Duchenne Muscular Dystrophy with the purpose of raising and appropriating funds for research to realize a cure. After almost 10 years of steady progress in the fight against this dreadful disease, the Jett Foundation has funded promising re...

Little Hercules Foundation and Team Joseph

Little Hercules Foundation is a registered, non-profit 501(c)(3) organization based in Dublin, Ohio. Little Hercules Foundation got its start in January 2013 when three moms, two of whom had sons diagnosed with Duchenne Muscular Dystrophy, decided to host events to help fund research. Since then, Little Hercules Foundation has grown into much more. We focu...

Summit Therapeutics plc

Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection.

Prosensa Holding N.V.

Prosensa is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease.

XDx, Inc.

Based in Brisbane, California, XDx is a molecular diagnostics company focused on the discovery, development and commercialization of noninvasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed a proprietary new method for noninvasively monitoring immune system activity by measuring g...

Solid GT

Solid GT, a subsidiary of Solid Biosciences, is a gene therapy platform focused on developing novel, disease-modifying therapeutics for Duchenne muscular dystrophy. The company’s licensed technology has demonstrated efficacy in various DMD animal models and lead candidates are currently undergoing IND-enabling studies. Founded in 2014, Solid GT is col...

Isotechnika Inc

Founded in 1993 by Dr. Robert Foster, Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada. Drawing upon its expertise in medicinal chemistry and immunology, the Company is focused on the discovery and development of novel immunosuppressive therapeutics that are safer than currently available treatments. Its entrepreneurial management and world-...

Santhera Pharmaceuticals Holding Ltd

Santhera Pharmaceuticals is a Swiss biopharmaceutical company focusing on the discovery, development and marketing of small molecule pharmaceutical products for the treatment of neuromuscular diseases. Santhera’s vision is to become the leading specialty pharmaceuticals company offering therapies for a number of indications in this area of high unmet medical need which includes many orphan indic...

Santarus, Inc. and Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST™ (RHUCIN® in non-European territories) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein. The product is also under development f...

Collaborative Trajectory Analysis Project


More From BioPortfolio on "Sarepta Therapeutics playing nice with over rejection Duchenne"

Quick Search

Corporate Database Quicklinks